EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 34 / No 1 (Janvier 2018) Med Sci (Paris), 34 1 (2018) 72-78 References
Free Access
Issue
Med Sci (Paris)
Volume 34, Number 1, Janvier 2018
Page(s) 72 - 78
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20183401016
Published online 31 January 2018
  1. Lahaie YM, Watier H. Contribution of physiologists to the identification of the humoral component of immunity in the 19th century. MAbs 2017; 9 : 774-80. [CrossRef] [PubMed] [Google Scholar]
  2. Von Behring E, Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals (1890). Mol Immunol 1991; 1317 : 1319-20. [Google Scholar]
  3. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 : 1643-7. [Google Scholar]
  4. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94 : 1914-8. [CrossRef] [Google Scholar]
  5. Lee YT, Sheikh KM, Quismorio FP Jr, Friou GJ. Circulating anti-tumor and autoantibodies in breast carcinoma: relationship to stage and prognosis. Breast Cancer Res Treat 1985; 6 : 57-65. [CrossRef] [PubMed] [Google Scholar]
  6. Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010; 17 : 121-34. [CrossRef] [PubMed] [Google Scholar]
  7. Karagiannis P, Gilbert AE, Josephs DH, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013; 123 : 1457-74. [CrossRef] [PubMed] [Google Scholar]
  8. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4 : 627-30. [CrossRef] [PubMed] [Google Scholar]
  9. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7 : 411-23. [CrossRef] [PubMed] [Google Scholar]
  10. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 2000; 12 : 597-605. [CrossRef] [PubMed] [Google Scholar]
  11. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity 2015; 42 : 607-12. [CrossRef] [PubMed] [Google Scholar]
  12. Shalapour S, Font-Burgada J, Di Caro G, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015; 521 : 94-8. [CrossRef] [PubMed] [Google Scholar]
  13. Watt V, Ronchese F, Ritchie D. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J Immunother 2007; 30 : 323-32. [CrossRef] [PubMed] [Google Scholar]
  14. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 2005; 238 : 67-75. [Google Scholar]
  15. Germain C, Gnjatic S, Tamzalit F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014; 189 : 832-44. [CrossRef] [PubMed] [Google Scholar]
  16. Shi JY, Gao Q, Wang ZC, et al. Margin-infiltrating CD20+ B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin Cancer Res 2013; 19 : 5994-6005. [CrossRef] [PubMed] [Google Scholar]
  17. Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology 2012; 1 : 1623-5. [CrossRef] [PubMed] [Google Scholar]
  18. Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic t-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res 2016; 22 : 3005-15. [CrossRef] [PubMed] [Google Scholar]
  19. Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 2017; 66 : 342-51. [CrossRef] [PubMed] [Google Scholar]
  20. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008; 20 : 332-8. [CrossRef] [PubMed] [Google Scholar]
  21. Ritchie DS, Yang J, Hermans IF, Ronchese F. B-lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8+ T-cells. Scand J Immunol 2004; 60 : 543-51. [CrossRef] [PubMed] [Google Scholar]
  22. Ahmadi T, Flies A, Efebera Y, Sherr DH. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I-and class II-binding peptides. Immunology 2008; 124 : 129-40. [CrossRef] [PubMed] [Google Scholar]
  23. Atanackovic D, Matsuo M, Ritter E, et al. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods 2003; 278 : 57-66. [CrossRef] [PubMed] [Google Scholar]
  24. Deola S, Panelli MC, Maric D, et al. Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 2008; 180 : 1362-72. [CrossRef] [PubMed] [Google Scholar]
  25. Lohr M, Edlund K, Botling J, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013; 333 : 222-8. [Google Scholar]
  26. Schmidt M, Hellwig B, Hammad S, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012; 18 : 2695-703. [CrossRef] [PubMed] [Google Scholar]
  27. Al-Shibli K, Al-Saad S, Andersen S, et al. The prognostic value of intraepithelial and stromal CD3-, CD117-and CD138-positive cells in non-small cell lung carcinoma. APMIS 2010; 118 : 371-82. [Google Scholar]
  28. Fristedt R, Borg D, Hedner C, et al. Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol 2016; 7 : 848-59. [CrossRef] [PubMed] [Google Scholar]
  29. Mohammed ZM, Going JJ, Edwards J, et al. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 2013; 109 : 1676-84. [CrossRef] [PubMed] [Google Scholar]
  30. Knief J, Reddemann K, Petrova E, et al. High density of tumor-infiltrating B-lymphocytes and plasma cells signifies prolonged overall survival in adenocarcinoma of the esophagogastric junction. Anticancer Res 2016; 36 : 5339-45. [CrossRef] [PubMed] [Google Scholar]
  31. Berntsson J, Nodin B, Eberhard J, et al. Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer 2016; 139 : 1129-39. [CrossRef] [PubMed] [Google Scholar]
  32. Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72 : 1070-80. [Google Scholar]
  33. Chen Z, Gerhold-Ay A, Gebhard S, et al. Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One 2012; 7 : e44741. [Google Scholar]
  34. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21 : 938-45. [CrossRef] [PubMed] [Google Scholar]
  35. Lundgren S, Berntsson J, Nodin B, et al. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. J Ovarian Res 2016; 9 : 21. [CrossRef] [PubMed] [Google Scholar]
  36. Pavoni E, Monteriu G, Santapaola D, et al. Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. BMC Biotechnol 2007; 7 : 70. [CrossRef] [PubMed] [Google Scholar]
  37. Mizukami M, Hanagiri T, Shigematsu Y, et al. Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth. Anticancer Res 2006; 26 : 1827-31. [PubMed] [Google Scholar]
  38. Carmi Y, Spitzer MH, Linde IL, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015; 521 : 99-104. [CrossRef] [PubMed] [Google Scholar]
  39. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110 : 71-9. [CrossRef] [PubMed] [Google Scholar]
  40. Lochner M, Ohnmacht C, Presley L, et al. Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells. J Exp Med 2011; 208 : 125-34. [CrossRef] [PubMed] [Google Scholar]
  41. McDonald KG, McDonough JS, Newberry RD. Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles. J Immunol 2005; 174 : 5720-8. [CrossRef] [PubMed] [Google Scholar]
  42. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39 : 782-95. [CrossRef] [PubMed] [Google Scholar]
  43. Meshcheryakova A, Tamandl D, Bajna E, et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One 2014; 9 : e99008. [CrossRef] [PubMed] [Google Scholar]
  44. Wirsing AM, Rikardsen OG, Steigen SE, et al. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC Clin Pathol 2014; 14 : 38. [CrossRef] [PubMed] [Google Scholar]
  45. Shalapour S, Lin XJ, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017; 551 : 340-5. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.